Fibronectin (rFN-CH296, NovoNectin) is involved in cell attachment, spreading, differentiation, and proliferation. It can greatly improve the infection efficiency of retroviruses on mammalian cells. VLA-4 and VLA-5 on the cell surface bind to the CS-1 site and the cell-binding domain on NovoNectin, respectively, and the retroviral vector binds to the heparin-binding domain, thus promoting the transfection efficiency of retroviruses and lentiviruses on cells. NovoNectin® can be mixed with anti-Human CD3 mAb for coating to enhance T cell amplification. Recombinant Human NovoNectin is expressed by E. coli, and is produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.